RT Journal Article
SR Electronic
A1 Alexander, Lori
T1 Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial
JF MD Conference Express
YR 2008
FD SAGE Publications
VO 8
IS 2
SP 12
OP 13
DO 10.1177/155989770800800209
UL http://mdc.sagepub.com/content/8/2/12.abstract
AB The angiotensin-receptor blocker telmisartan is equally effective in reducing cardiovascular risk as the angiotensin-converting enzyme inhibitor ramipril in patients with vascular disease or high-risk diabetes. However, the combination is no more effective than either drug alone and causes more side effects according to results from the ONTARGET Trial.